Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Civitas Therapeutics, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)

Phase 1

Completed

Conditions: Parkinson's Disease

Interventions: Drug: Sinemet
Drug: CVT-301

First Posted Date: 2019-03-25

Last Posted Date: 2019-08-02

Lead Sponsor: Acorda Therapeutics

Target Recruit Count: 23

Registration Number: NCT03887884

Locations: 🇺🇸
Acorda Site #1003, Long Beach, California, United States
🇺🇸
Acorda Site #1005, Hallandale Beach, Florida, United States
🇺🇸
Acorda Site #1002, Orlando, Florida, United States

and more 2 locations

A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder

Phase 1

Completed

Conditions: Migraine

Interventions: Drug: CVT-427 (zolmitriptan inhalation powder)

First Posted Date: 2016-09-19

Last Posted Date: 2018-02-14

Lead Sponsor: Acorda Therapeutics

Target Recruit Count: 60

Registration Number: NCT02905227

Locations: 🇺🇸
Site #103, North Dartmouth, Massachusetts, United States
🇺🇸
Site #102, Lincoln, Nebraska, United States
🇺🇸
Site #101, Dallas, Texas, United States

A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets

Phase 1

Completed

Conditions: Parkinson Disease

Interventions: Drug: CVT-301 (Dose Level 1)
Drug: CVT-301 (Dose Level 2)
Drug: Sinemet®

First Posted Date: 2016-06-24

Last Posted Date: 2016-10-26

Lead Sponsor: Acorda Therapeutics

Target Recruit Count: 24

Registration Number: NCT02812394

Locations: 🇺🇸
Site #001, Dallas, Texas, United States

A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)

Phase 1

Completed

Conditions: Parkinson's Disease

Interventions: Drug: CVT-301, LIP
Other: Placebo

First Posted Date: 2016-06-21

Last Posted Date: 2017-01-30

Lead Sponsor: Acorda Therapeutics

Target Recruit Count: 36

Registration Number: NCT02807675

Locations: 🇺🇸
Site #9015, Fountain Valley, California, United States
🇺🇸
Site #9002, Boca Raton, Florida, United States
🇺🇸
Site #9017, Hallandale, Florida, United States

and more 8 locations

A Pharmacokinetic Study to Assess Dose Proportionality, Safety and Tolerability of Diazepam Nasal Spray in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: diazepam nasal spray

First Posted Date: 2016-01-26

Last Posted Date: 2016-06-13

Lead Sponsor: Acorda Therapeutics

Target Recruit Count: 15

Registration Number: NCT02663999

Locations: 🇺🇸
Site #001, Dallas, Texas, United States

A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With Asthma

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: CVT-301 (levodopa inhalation powder)
Drug: Carbidopa
Other: Placebo

First Posted Date: 2015-12-17

Last Posted Date: 2016-06-13

Lead Sponsor: Acorda Therapeutics

Target Recruit Count: 25

Registration Number: NCT02633007

Locations: 🇺🇸
Site 002, Daytona Beach, Florida, United States
🇺🇸
Site 001, North Dartmouth, Massachusetts, United States
🇺🇸
Site 003, Dallas, Texas, United States

A Study of the Safety and Levodopa Pharmacokinetics Following Single Dose Administration of CVT 301 (Levodopa Inhalation Powder) in Smoking and Non-Smoking Adults

Phase 1

Completed

Conditions: Smoking

Interventions: Drug: CVT-301
Drug: Carbidopa

First Posted Date: 2015-12-17

Last Posted Date: 2016-07-14

Lead Sponsor: Acorda Therapeutics

Target Recruit Count: 60

Registration Number: NCT02633839

Locations: 🇺🇸
Site 001, Daytona Beach, Florida, United States
🇺🇸
Site 002, Dallas, Texas, United States

Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults

Phase 1

Completed

Conditions: Migraine

Interventions: Drug: zolmitriptan
Drug: CVT-427 (zolmitriptan inhalation powder),

First Posted Date: 2015-11-20

Last Posted Date: 2016-06-06

Lead Sponsor: Acorda Therapeutics

Target Recruit Count: 21

Registration Number: NCT02609945

Locations: 🇺🇸
Site 001, Daytona Beach, Florida, United States
🇺🇸
Site 002, Dallas, Texas, United States

Bioavailability, Safety and Tolerability of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®)

Phase 2

Terminated

Conditions: Refractory Epilepsy

Interventions: Drug: diazepam rectal gel
Drug: diazepam nasal spray

First Posted Date: 2015-06-17

Last Posted Date: 2018-10-16

Lead Sponsor: Acorda Therapeutics

Target Recruit Count: 78

Registration Number: NCT02474407

Locations: 🇺🇸
Acorda Site #115, Little Rock, Arkansas, United States
🇺🇸
Acorda Site #127, Washington, District of Columbia, United States
🇺🇸
Acorda Site #101, Tampa, Florida, United States

and more 19 locations

Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine.

Phase 3

Terminated

Conditions: Post-ischemic Stroke

Interventions: Drug: dalfampridine-ER 10 mg
Drug: dalfampridine-ER 7.5 mg

First Posted Date: 2015-04-22

Last Posted Date: 2019-01-22

Lead Sponsor: Acorda Therapeutics

Target Recruit Count: 294

Registration Number: NCT02422940

Locations: 🇺🇸
Acorda Site #117, Gilbert, Arizona, United States
🇺🇸
Acorda Site #109, Berkeley, California, United States
🇺🇸
Acorda Site #170, Carlsbad, California, United States

and more 63 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy